From this page you can:
Add the result to your basket Make a suggestion Refine your search Apply to external sources
Extend search on down-posting(s)
Analyse socio-économique des dépenses d'hospitalisation en 1992 / Anne Aligon / Paris : CREDES (1997)
Analyse socio-économique des dépenses d'hospitalisation en 1992 [printed text] / Anne Aligon, Author ; Nathalie Grandfils, Author . - Paris : CREDES, 1997 . - 94 p.. - (Biblio; 1157) .
ISBN : 978-2-87812-203-9
Languages : French
WX 157 Financial administration. Business management. Cost accounting
Data Collection ; Economic Evaluation ; Economics, Hospital ; France ; Hospital Costs
Record link: http://kce.docressources.info/index.php?lvl=notice_display&id=1169
HoldPlace a hold on this item
Barcode Call number Media type Location Section Status 10273-00270 WX 157/ALI Report KCE Library (10.124) AvailableAssessing the economic value of anti-cancer therapies / Niels Neymark / New York ; Berlin ; Tokyo : Springer (1998)
Assessing the economic value of anti-cancer therapies [printed text] / Niels Neymark . - New York ; Berlin ; Tokyo : Springer, 1998 . - XI, 285 p. ; 23 cm. - (Recent results in cancer research; 148) .
ISBN : 978-3-540-64030-1
Languages : English
QZ 266 Neoplasms. Cysts -- Therapy
Antineoplastic Agents ; Cost-Benefit Analysis ; Costs and Cost Analysis ; Economic Evaluation ; Health Care Costs ; Neoplasms
Abstract: BOOK REVIEW Kevin B. Knopf, JNCI, 1999, 91(14), 1248-1249
The need for accurate economic analysis to guide health care delivery is irrefutable, since health care costs continue to rise in parallel with a growing demand in value for our spending. Cancer care accounts for 5%-10% of all health care dollars spent in the United States, and although breakthroughs in cancer research will provide much needed improvements in the treatment of cancer, they will also come at a cost. Dr. Neymark speaks in his preface of the "aura of sanctity" surrounding cancer so that "everything possible" is done for the patients. This aura derives partly from the seriousness of the disease and the fear surrounding a diagnosis of cancer. However, a need for high-quality economic research in cancer care is still necessary to guide rational resource allocation, and this text succeeds in succinctly and thoughtfully summarizing the state of the art of economic analysis of cancer therapies. By exploring the literature related to economic evaluation of cancer therapies over a 10-year period, Dr. Neymark has provided a great deal of food for thought for research in this area.
The general nature of economic evaluation is defined in the introduction:
"Economic evaluation is a widely applicable economic method concerned with the comparison of two or more alternatives with respect to both their positive and negative impacts or benefits and costs, respectively, as these impacts are generally termed. It is the presence of alternative methods of treatments that create an economic problem."
It is the presence of choices that makes economic evaluation a valuable tool. In the past, the treatment of cancer, particularly metastatic disease, was limited in the number of options available, as the author notes. However, new treatments are continually being developed, which come with a cost versus benefit trade-off, and thus economic evaluations will assume a greater importance as our therapeutic choices increase.
The very brief chapter on the epidemiology of cancer could have been made more substantial, and the addition of graphs to interpret trends would have been useful. The following chapter provides an excellent overview of the nature of cancer and its major treatment modalities, which will be of interest to the nonclinician.
The chapters on economic evaluation and the economic burden of cancer are well written and serve as solid introductions for the novice to these areas and a good review for others. He describes the rationale and methods behind the cost-of-illness studies, which he treats with a healthy skepticism. A lengthy section on economic evaluation covers important concepts and describes, in turn, the four major types of studies: cost-minimization, cost-benefit, cost-effectiveness, and cost-utility, the latter two being the most appropriate type of study for most cancer therapeutics. Discussion about methodology involved in collecting data for cost and outcomes, perspective of the analysis, valuation, and presentation and interpretation of results of economic evaluations are also well written.
The heart of the text is a thorough discussion of the major economic studies of cancer treatment published from 1985 to 1996. The author reviews the relevant literature pertaining to costs and treatment of most of the major malignancies, including relevant supportive care areas. Topics covered include the following: breast cancer (14 studies), lung cancers (eight studies), colorectal cancer (eight studies), prostate cancer (10 studies), genitourinary and gynecologic malignancies (11 studies), leukemias and lymphomas (10 studies), therapies for emesis and infections (nine studies), hematologic support and transplantation (18 studies), and palliative care (five studies). Every section is preceded by an overview of treatment options that are fairly accurate—although not without occasional omissions and errors; these sections will be invaluable for the nonclinician.
Each study is described concisely, including rationale, type of analysis, perspective, techniques, data sources, and results, when stated by the original authors. Dr. Neymark justly criticizes studies with conceptual or methodologic flaws, erroneous assumptions, or clear oversights in the evaluation, and as a critical reviewer, he certainly holds no punches. This lengthy and in-depth review of a body of work makes his text a compelling read and enables the reader to gain a great deal of insight into how to, and often how not to, evaluate the economics of cancer therapeutics. Through reading his summation of the body of literature, one obtains an appreciation of not only what studies have been performed and which studies should be performed but also a sense of the "state of the art of the methodology" currently in use. Each chapter closes with a concise table of the articles reviewed and concluding comments that highlight the strengths and weaknesses in the studies, comparing studies when appropriate, and pointing out possible future directions.
A concluding chapter discusses some of the broader controversies, which have been hinted at throughout the review, in an insightful manner. The use of "league tables" to compare cost-effectiveness ratios is justly criticized, due to the implicit assumption of comparability of studies. The issue of costs versus charges is briefly discussed, and a lengthy discussion of the merits of collecting economic data in clinical trials points to the complementary benefit of modeling. The nature of outcomes used, e.g., the inapplicability of life-years saved as an outcome to evaluate antiemetic therapies, is also explored.
By design, this review cannot serve as a complete "how to" guide for economic evaluations, although there are many pearls to be gained from a thorough reading. The economics of cancer prevention and screening, which are in many ways more difficult to study from an economic perspective, were not explored in this text, but there are other sources for this information.
Many of the reviewed studies are excellent and may serve as an aide to treatment choices for a specific situation. In a broader sense, this book will be extremely valuable for both the health service researcher who wishes to learn about cancer economics and the cancer researcher interested in the economic aspects of their field. By reviewing 9 years of the literature in a systematic, thoughtful, and critical manner, there is much to be gained for the interested reader who invests a small amount of time reading this excellent work.
Record link: http://kce.docressources.info/index.php?lvl=notice_display&id=244
HoldPlace a hold on this item
Barcode Call number Media type Location Section Status 10273-00306 QZ 266/NEY Book KCE Library (10.124) AvailableBase CODECS (COnnaissances et Décisions en EConomie de la Santé) / Collège des économistes de la santé (CES)
Base CODECS (COnnaissances et Décisions en EConomie de la Santé) [electronic document] . - [S.l.] : Collège des économistes de la santé (CES) : France : INSERM, [s.d.].
Languages : English French
W 26.55.I4 Information systems. Information storage and retrieval
Databases, Bibliographic ; Economic Evaluation
Link for e-copy: http://infodoc.inserm.fr/codecs/codecs.nsf Format of e-copy: Online [Open Access] Record link: http://kce.docressources.info/index.php?lvl=notice_display&id=1083Belgian guidelines for budget impact analyses / Mattias Neyt in Acta Clinica Belgica, 70(2015)03 ([06/01/2015])
[article] Belgian guidelines for budget impact analyses [printed text] / Mattias Neyt , Author ; Irina Cleemput ; Stefaan Van de Sande ; Nancy Thiry . - 2015 . - 175-180.
Languages : English
in Acta Clinica Belgica > 70(2015)03 [06/01/2015] . - 175-180
W 1 Serials. Periodicals
2011-44 ; Belgium ; Budgets ; Economic Evaluation ; Journal Article ; Practice Guideline [Publication type] ; R183 ; Reimbursement Mechanisms
Abstract: Objectives: To develop methodological guidelines for budget impact analysis submitted to the Belgian health authorities as part of a reimbursement request. Methods: A review of the literature was performed and provided the basis for preliminary budget impact guidelines. These guidelines were improved after discussion with health economists from the Belgian Health Care Knowledge Centre (KCE) and different Belgian stakeholders from both government and industry. Preliminary guidelines were also discussed in a workshop with health economists from The German Institute for Quality and Efficiency in Healthcare. Finally, the guidelines were also externally validated by three external experts. Results: The guidelines give explicit guidance for the following components of a budget impact analysis: perspective of the evaluation, target population, comparator, costs, time horizon, modeling, handling uncertainty and discount rate. Special attention is given to handling varying target population sizes over time, applying a time horizon up to the steady state instead of short-term predictions, and similarities and differences between budget impact analysis and economic evaluations. Conclusion: The guidelines provide a framework for both researchers and assessors to set up budget impact analyses that are transparent, relevant, of high quality and apply a consistent methodology. This might improve the extent to which such evaluations can reliably and consistently be used in the reimbursement decision making process. Link for e-copy: http://dx.doi.org/10.1179/2295333714Y.0000000118 Format of e-copy: PDF [Requires Subscription) Record link: http://kce.docressources.info/index.php?lvl=notice_display&id=3662[article]Deux essais sur la valeur économique de la prévention / Philippe Godfroid / Mons [Belgium] : Facultés Universitaires Catholiques de mons (FUCaM) (1997)
Deux essais sur la valeur économique de la prévention [printed text] / Philippe Godfroid, Author ; Louis Eeckhoudt, Thesis advisor ; Christian Gollier, Thesis advisor . - Mons (7000, Belgium) : Facultés Universitaires Catholiques de mons (FUCaM), 1997 . - 124 p.
ISSN : 337
Thèse de doctorat, disseration présentée pour l'obtention du grade de docteur en Sciences économiques
Languages : French
W 74 Medical economics. Health care costs (General)
Academic Dissertations ; Economic Evaluation ; Economics ; Preventive Medicine
Record link: http://kce.docressources.info/index.php?lvl=notice_display&id=256
HoldPlace a hold on this item
Barcode Call number Media type Location Section Status 10273-00337 W 74/GOD Book KCE Library (10.124) AvailableDevelopment and Testing of Search Filters to Identify Economic Evaluations in MEDLINE and EMBASE / Julie Glanville / Ottawa [Canada] : Canadian Agency for Drugs and Technologies in Health - (CADTH) (2009)PermalinkEconomic analysis in health care / Stephen Morris / Chichester : J. Wiley (2007)PermalinkEconomic crisis, health systems and health in Europe / Sarah Thomson / Mc Graw Hill Education (2015)PermalinkEconomische evaluatie van de geneesmiddelenconsumptie 2003-2006 / Joëlle Benda / Bruxelles [Belgium] : Unie Onafhankelijke Ziekenfondsen - Union des Mutualités Libres - MLOZ (2007)PermalinkEUnetHTA HTA Adaptation Toolkit & Glossary / London [UK] : National Health Services (NHS) (Octobre 2011)PermalinkEvaluation économique de la consommation des médicaments 2003-2006 / Joëlle Benda / Bruxelles [Belgium] : Unie Onafhankelijke Ziekenfondsen - Union des Mutualités Libres - MLOZ (2007)PermalinkFinancing long-term care in Europe / Joan Costa-Font / New York [United State] : Macmillan : Metropolitan Books (2012)PermalinkGéographie de la consommation médicale / Rodrigo Ruz Torres / Bruxelles [Belgium] : Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (RIZIV) = Institut National Maladie Invalidité (INAMI) (2006)PermalinkGéographie de la consommation médicale / Bruxelles [Belgium] : Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (RIZIV) = Institut National Maladie Invalidité (INAMI) (2012)PermalinkNew Health Technologies / Paris : OECD publications (2017)Permalink